Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.67M Buy
22,613
+9,009
+66% +$1.04M 0.01% 872
2026
Q1
$1.63M Buy
13,604
+910
+7% +$119K 0.01% 1017
2025
Q4
$1.73M Buy
12,694
+2,332
+23% +$335K 0.01% 933
2025
Q3
$1.53M Buy
10,362
+314
+3% +$43.5K 0.01% 880
2025
Q2
$1.3M Buy
10,048
+1,523
+18% +$184K 0.01% 862
2025
Q1
$1.02M Sell
8,525
-1,650
-16% -$204K 0.01% 820
2024
Q4
$1.19M Buy
10,175
+2,857
+39% +$361K 0.01% 697
2024
Q3
$985K Sell
7,318
-1,950
-21% -$261K 0.02% 574
2024
Q2
$1.25M Buy
9,268
+5,470
+144% +$744K 0.05% 292
2024
Q1
$491K Buy
+3,798
New +$459K 0.07% 271

Other funds holding XYL

&Partners's XYL Position: Q2 2026 in Review

&Partners increased its Xylem (XYL) stake by 66% in Q2 2026, buying an estimated $1.04M and bringing the position to 22,613 shares worth $2.67M. The position accounts for 0.01% of the portfolio, ranked #872.

&Partners first reported a position in XYL in Q1 2024 and has held it in 10 quarters since. 1,093 funds tracked by Wall St. Rank hold XYL as of Q2 2026.

  • &Partners held 22,613 shares of Xylem worth $2.67M as of Q2 2026.
  • &Partners bought 9,009 Xylem shares in Q2 2026, an estimated $1.04M.
  • Xylem made up 0.01% of &Partners's portfolio in Q2 2026, its #872 holding.
  • &Partners first reported a position in Xylem in Q1 2024 and has held it in 10 quarters since.
  • 1,093 funds tracked by Wall St. Rank held Xylem as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.